References
- Prescribing practices. Centers for Disease Control and Prevention; 2021 June 23. https://www.cdc.gov/drugoverdose/deaths/prescription/practices.html.
- CDC timeline. Centers for Disease Control and Prevention; 2020 November 4. https://www.cdc.gov/museum/timeline/covid19.html.
- New Jersey announces first presumptive case of COVID-19 coronavirus. FOX 5 New York; 2020 March 5. https://www.fox5ny.com/news/new-jersey-announces-first-presumptive-case-of-covid-19-coronavirus.
- Macmadu A, Batthala S, Correia Gabel AM, Rosenberg M, Ganguly R, Yedinak JL, Hallowell BD, Scagos RP, Samuels EA, Cerdá M, et al. Comparison of characteristics of deaths from drug overdose before vs during the COVID-19 pandemic in Rhode Island. JAMA Netw Open. 2021;4(9):e2125538. doi:10.1001/jamanetworkopen.2021.25538.
- DiGennaro C, Garcia GP, Stringfellow EJ, Wakeman S, Jalali MS. Changes in characteristics of drug overdose death trends during the COVID-19 pandemic. Int J Drug Policy. 2021;98:103392. 10.1016/j.drugpo.2021.103392.
- Coronavirus Disease 2019. Centers for Disease Control and Prevention; 2020 December 21. https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html.
- Substance use during the pandemic. n.d. https://www.apa.org. https://www.apa.org/monitor/2021/03/substance-use-pandemic.
- Czeisler MÉ, Lane RI, Petrosky E, Wiley JF, Christensen A, Njai R, Weaver MD, Robbins R, Facer-Childs ER, Barger LK, et al. Mental health, substance use, and suicidal ideation during the COVID-19 pandemic—United States, June 24–30, 2020. MMWR - Morb Mortal Wkly Rep. 2020;69(32):1049–57. http://doi.org/10.15585/mmwr.mm6932a1externalicon.
- Grief and Loss. Centers for Disease Control and Prevention; 2021 August 6. https://www.cdc.gov/mentalhealth/stress-coping/grief-loss/index.html.
- Samuels EA, Clark SA, Wunsch C, Jordison Keeler LA, Reddy N, Rahul V, Wightman RS. Innovation during COVID-19: improving addiction treatment access. J Addict Med. 2020;14(4):e8–e9. doi:10.1097/ADM.0000000000000685.
- Deutsch AJ, Gajdosik DA, Ramdin C, Tebo C, Mazer-Amirshahi M, Fox ER, Colorado J, Nelson LS, Perrone J. The impact of the parenteral opioid medication shortages on opioid utilization practices in the emergency department of two university hospitals. J Med Toxicol. 2021;17(4):372–7. 10.1007/s13181-021-00842-7.
- FDA advises patients on use of NSAIDs for COVID-19. U.S. Food and Drug Administration; 2020 March 19. https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19.
- Mehta B, Jannat-Khah D, Mancuso CA, Bass AR, Moezinia CJ, Gibofsky A, Goodman SM, Ibrahim S. Geographical variations in COVID-19 perceptions and patient management: a national survey of rheumatologists. Semin Arthritis Rheum. 2020;50(5):1049–54. doi:10.1016/j.semarthrit.2020.06.017.
- Lund LC, Kristensen KB, Reilev M, Christensen S, Thomsen RW, Christiansen CF, Støvring H, Johansen NB, Brun NC, Hallas J, et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: a Danish nationwide cohort study. PLoS Med. 2020;17(9):e1003308. doi:10.1371/journal.pmed.1003308.
- Wong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, Brown JP, Rentsch CT, Williamson E, Drysdale H, OpenSAFELY Collaborative, et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021;80(7):943–51. 10.1136/annrheumdis-2020-219517.
- Ramdin C, Muckey E, Rosania A, Nelson L. Trends in visits related to drug use adverse effects in an urban ED during COVID-19. Am J Emerg Med. 2022;53(21):264–5. doi:10.1016/j.ajem.2021.04.067.